Patents by Inventor Guohua Zhao

Guohua Zhao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190314346
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Application
    Filed: June 19, 2019
    Publication date: October 17, 2019
    Inventors: Huji Turdi, Jon J. Hangeland, R. Michael Lawrence, Saleem Ahmad, Wei Meng, Robert Paul Brigance, Pratik Devasthale, Guohua Zhao
  • Publication number: 20190300777
    Abstract: The present invention provides a phase transition material fluid and a proppant formed therefrom, wherein the components for preparing the phase transition material fluid comprise in percentages by mass: a supramolecular building block 10 to 60 wt %, a supramolecular functional unit 20 to 50 wt %, a dispersant 0.1 to 2 wt %, an inorganic co-builder 0.1 to 1 wt %, an initiator 0.1 to 1 wt %, the balance being a solvent. The supramolecular building block comprises a melamine-based substance and/or a triazine-based substance; the supramolecular functional unit comprises a dicyclopentadiene resin; and the dispersant includes a hydroxyl-bearing polysaccharide substance and a surfactant. After the phase transition material fluid enters the reservoir, it may form a solid substance to prop the fracture under the action of supramolecular chemistry and physics.
    Type: Application
    Filed: March 27, 2019
    Publication date: October 3, 2019
    Applicant: PetroChina Company Limited
    Inventors: Shubao HU, Yong YANG, Liqiang ZHAO, Guohua LIU, Mengmeng NING, Kun XU, Juan DU, Ning LI, Lina ZHANG, Yuanzhao JIA
  • Publication number: 20190297612
    Abstract: Embodiments of this application disclose a downlink control channel indication method, a terminal device, and a network device. The method includes: receiving, by a terminal device, indication information sent by a network device on a preset frequency band of a first time frequency resource, where the first time frequency resource partially or completely overlaps with a second time frequency resource; and determining, by the terminal device, a location of a physical downlink control channel (PDCCH) time frequency resource of the first time frequency resource according to the indication information. In the technical solutions of this application, the terminal device of the first time frequency resource can determine the location of the PDCCH time frequency resource.
    Type: Application
    Filed: June 14, 2019
    Publication date: September 26, 2019
    Inventors: Guohua ZHOU, Hao TANG, Yinan ZHAO, Zhe LIU
  • Publication number: 20190287465
    Abstract: The present application provides a scan driver, a driving method thereof and an organic light emitting display. The scan driver includes a first driving area and a second driving area. The first driving area includes a number of first driving units, and the number of the first driving units sequentially sends a first driving signal and a third driving signal to a scan line. The second driving area includes a number of second driving units, and the number of the second driving units sequentially sends a second driving signal to the scan line.
    Type: Application
    Filed: May 31, 2019
    Publication date: September 19, 2019
    Inventors: Guohua ZHAO, Siming HU, Lu ZHANG, Zhenzhen HAN, Hui ZHU
  • Publication number: 20190270741
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to ?v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ?v-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
    Type: Application
    Filed: November 7, 2017
    Publication date: September 5, 2019
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Pratik DEVASTHALE, Fang MOORE, Guohua ZHAO, Susan Nicole PIENIAZEK, Kumaravel SELVAKUMAR, Suresh DHANUSU, Manoranjan PANDA, Lawrence R. MARCIN
  • Publication number: 20190263808
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to ?v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ay-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
    Type: Application
    Filed: November 7, 2017
    Publication date: August 29, 2019
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Guohua ZHAO, Pratik DEVASTHALE, Xiang-Yang YE, Kumaravel SELVAKUMAR, Suresh DHANUSU, Palanikumar BALASUBRAMANIAN, Leatte R. GUERNON, Rita CIVIELLO, Xiaojun HAN, Michael Frederick PARKER, Swanee E. JACUTIN-PORTE
  • Publication number: 20190256512
    Abstract: The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are inhibitors to ?v-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ?v-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
    Type: Application
    Filed: November 7, 2017
    Publication date: August 22, 2019
    Inventors: Guohua Zhao, James Mignone
  • Publication number: 20190261372
    Abstract: The present invention relates to the field of wireless communications technologies, and provides a method for transmitting a carrier, a base station, user equipment, and a system. The method discloses: sending, by a base station, a second carrier, where the second carrier at least partially shares a same resource area with a first carrier, the resource area includes a plurality of resource elements, and the first carrier and the second carrier occupy different resource elements; and sending, by the base station, blank resource element indication information to user equipment that receives the second carrier, where the blank resource element indication information is used to indicate a position of a resource element occupied by the first carrier in the shared resource area. According to the solutions provided in the embodiments, a resource utilization rate of a communications system is improved, and interference between carriers is avoided.
    Type: Application
    Filed: April 29, 2019
    Publication date: August 22, 2019
    Inventors: Guohua Zhou, Zhenfei Tang, Yueying Zhao, Hao Tang, Peng Zhang, Dongdong Wei
  • Patent number: 10369140
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: August 6, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Huji Turdi, Jon J. Hangeland, R. Michael Lawrence, Saleem Ahmad, Wei Meng, Robert Paul Brigance, Pratik Devasthale, Guohua Zhao
  • Patent number: 10364388
    Abstract: The present invention discloses a phase change fracturing fluid system for phase change fracturing, including the following components in percentage by weight: 10%-40% of supramolecular construction unit, 0-40% of supramolecular function unit, 0.5%-2% of surfactant, 0-5% of inorganic salt, 0.5%-2% of oxidizing agent, 0-2% of cosolvent and the remaining of solvent. The supramolecular construction unit is melamine, triallyl isocyanurate, or a mixture thereof. The supramolecular function unit is vinyl acetate, acrylonitrile, or a mixture thereof. The solvent is methylbenzene, ethylbenzene, o-xylene, m-xylene or p-xylene. In the fracturing construction process, a conventional fracturing fluid is used for fracturing a formation first; the phase change fracturing fluid is then injected into the formation, or the phase change fracturing fluid and other fluids which cannot be subjected to phase change are injected into the formation together.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: July 30, 2019
    Assignee: SOUTHWEST PETROLEUM UNIVERSITY
    Inventors: Liqiang Zhao, Yong Yang, Guangyan Du, Donghe Yu, Juan Du, Hang Che, Zhifeng Luo, Guohua Liu, Yuxin Pei, Nianyin Li, Pingli Liu, Kun Xu
  • Patent number: 10301919
    Abstract: A phase-change hydraulic fracturing process, including the following steps: (1) injecting clean water or conventional fracturing fluid to a formation, so that the formation fractures; (2) placing non-phase-change liquid and phase-change liquid in different liquid mixing tanks and injecting into a shaft at the same time, an injection volume ratio of the non-phase-change liquid to the phase-change liquid is (0-0.7):(0.3-1); (3) injecting a displacement fluid into the shaft, so that the non-phase-change liquid and the phase-change liquid in the shaft completely enter a reservoir; (4) performing well shut-in and pressure-out for 30-200 min, so that solid-phase matters generated by the phase-change liquid are laid in the fracture; and (5) relieving pressure to finish the construction.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: May 28, 2019
    Assignee: SOUTHWEST PETROLEUM UNIVERSITY
    Inventors: Liqiang Zhao, Yong Yang, Zhifeng Luo, Donghe Yu, Juan Du, Guohua Liu, Hang Che, Guangyan Du, Yuxin Pei, Nianyin Li, Pingli Liu, Kun Xu, Bingxiao Liu
  • Publication number: 20190127358
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
    Type: Application
    Filed: October 31, 2018
    Publication date: May 2, 2019
    Inventors: David S. Yoon, Rushith Kumar Anumula, Srinivas Cheruku, Yanting Huang, Elizabeth Anne Jurica, Wei Meng, Susheel Jethanand Nara, Rishikesh Narayan, Ramesh Kumar Sistla, Ximao Wu, Guohua Zhao
  • Publication number: 20180133198
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Application
    Filed: January 11, 2018
    Publication date: May 17, 2018
    Inventors: Huji Turdi, Jon J. Hangeland, R. Michael Lawrence, Saleem Ahmad, Wei Meng, Robert Paul Brigance, Pratik Devasthale, Guohua Zhao
  • Patent number: 9901572
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: February 27, 2018
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Huji Turdi, Jon J. Hangeland, R. Michael Lawrence, Saleem Ahmad, Wei Meng, Robert Paul Brigance, Pratik Devasthale, Guohua Zhao
  • Patent number: 9856244
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: January 2, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Wei Meng, Guohua Zhao
  • Publication number: 20170267666
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Application
    Filed: June 8, 2017
    Publication date: September 21, 2017
    Inventors: Wei Meng, Guohua Zhao
  • Publication number: 20170216263
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Application
    Filed: April 17, 2017
    Publication date: August 3, 2017
    Inventors: Huji Turdi, Jon J. Hangeland, R. Michael Lawrence, Dong Cheng, Saleem Ahmad, Wei Meng, Robert Paul Brigance, Pratik Devasthale, Guohua Zhao
  • Patent number: 9701672
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Grant
    Filed: March 5, 2015
    Date of Patent: July 11, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Wei Meng, Guohua Zhao
  • Patent number: 9663466
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: May 30, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Huji Turdi, Jon J. Hangeland, R. Michael Lawrence, Saleem Ahmad, Wei Meng, Robert Paul Brigance, Pratik Devasthale, Guohua Zhao
  • Patent number: 9586900
    Abstract: The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are melanin concentrating hormone receptor-1 (MCHR1) antagonists which may be used as medicaments.
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: March 7, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Saleem Ahmad, Guohua Zhao, William N. Washburn